Treatment Benefits of the remedē® System Sustained Through 36 Months in Patients with Central Sleep Apnea
Respicardia Also Initiates 500-Patient Prospective, Global, Single-Arm Longitudinal Study
remedē News
CMS Grants Outpatient Pass-through Payment to the remedē® System for the Treatment of Central Sleep Apnea
Pass-through Payment to Provide Additional Medicare Reimbursement for the remedē System
CMS Grants New Technology Add-on Payment to the remedē® System for the Treatment of Central Sleep Apnea
Add-on Payment to Provide Additional Medicare Reimbursement for the remedē System
Respicardia Announces First U.S. Commercial Case With The remedē® System
Industry Veteran Peter Sommerness Joins as CEO to Lead U.S. Launch
Respicardia Closes $58.5 Million In Financing To Treat Central Sleep Apnea
Company announces strategic relationship with ZOLL Medical